WUXAY Stock - WuXi AppTec Co., Ltd.
Unlock GoAI Insights for WUXAY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $39.24B | $40.34B | $39.35B | $22.90B | $16.54B |
| Gross Profit | $16.28B | $16.57B | $14.68B | $8.31B | $6.28B |
| Gross Margin | 41.5% | 41.1% | 37.3% | 36.3% | 38.0% |
| Operating Income | $11.58B | $11.87B | $10.65B | $6.04B | $3.39B |
| Net Income | $9.45B | $9.61B | $8.81B | $5.10B | $2.96B |
| Net Margin | 24.1% | 23.8% | 22.4% | 22.3% | 17.9% |
| EPS | $3.28 | $3.24 | $3.01 | $1.75 | $1.06 |
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
WUXAYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 27, 2026 | — | — | — | — |
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Oct 31, 2025 | $0.15 | $0.02 | -84.1% | ✗ MISS |
Q2 2025 | Apr 28, 2025 | $0.11 | $0.18 | +63.5% | ✓ BEAT |
Q4 2024 | Dec 31, 2024 | — | $0.14 | — | — |
Q4 2024 | Oct 28, 2024 | $0.12 | $0.11 | -2.8% | ✗ MISS |
Q3 2024 | Jul 29, 2024 | $0.11 | $0.11 | +1.2% | ✓ BEAT |
Q2 2024 | Apr 29, 2024 | $0.10 | $0.09 | -6.8% | ✗ MISS |
Q1 2024 | Jan 5, 2024 | — | $0.07 | — | — |
Q3 2023 | Sep 30, 2023 | $0.13 | $0.13 | +2.4% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $0.12 | $0.14 | +21.7% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $0.11 | $0.10 | -5.6% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $0.07 | — | — |
Q3 2022 | Sep 30, 2022 | $0.10 | $0.11 | +18.2% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $0.11 | $0.14 | +29.1% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $0.07 | $0.08 | +11.5% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $0.08 | — | — |
Q3 2021 | Sep 30, 2021 | — | $0.05 | — | — |
Q2 2021 | Jun 30, 2021 | — | $0.06 | — | — |
Q1 2021 | Mar 31, 2021 | — | $0.08 | — | — |
Latest News
Frequently Asked Questions about WUXAY
What is WUXAY's current stock price?
What is the analyst price target for WUXAY?
What sector is WuXi AppTec Co., Ltd. in?
What is WUXAY's market cap?
Does WUXAY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to WUXAY for comparison